Statements (55)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:biotechnology
|
gptkbp:administered_by |
Healthcare professionals
Intravenous infusion Patients with cancer |
gptkbp:approves |
gptkb:FDA
|
gptkbp:developed_by |
gptkb:biotechnology
Various pharmaceutical companies |
gptkbp:has_similar_efficacy_to |
gptkb:Rituximab
|
https://www.w3.org/2000/01/rdf-schema#label |
Biosimilar to Rituximab
|
gptkbp:ingredients |
gptkb:Oncology
|
gptkbp:is_available_in |
Multiple countries
|
gptkbp:is_biosimilar_to |
gptkb:Rituximab
|
gptkbp:is_compared_to |
Original biologic
Reference product |
gptkbp:is_considered |
Affordable treatment option
Alternative to branded drug Cost-effective alternative Effective treatment option Innovative treatment option Patient-friendly option Standard of care Therapeutic equivalent |
gptkbp:is_evaluated_by |
Safety
Cost-effectiveness Immunogenicity Pharmacodynamics Pharmacokinetics Efficacy Long-term outcomes |
gptkbp:is_part_of |
gptkb:health_services
Treatment guidelines Patient care plans Pharmaceutical market Biologics category Cancer treatment regimens Monoclonal antibody therapy |
gptkbp:is_regulated_by |
Health authorities
|
gptkbp:is_subject_to |
Clinical trials
Market competition Quality control measures Post-marketing surveillance Regulatory approval process |
gptkbp:is_used_for |
gptkb:Non-Hodgkin_lymphoma
gptkb:Chronic_lymphocytic_leukemia |
gptkbp:is_used_in |
gptkb:Oncology
gptkb:Doctor Autoimmune diseases Rheumatology Clinical trials for new indications Infusion centers |
gptkbp:marketed_as |
Pharmaceutical companies
Different brand names |
gptkbp:safety_features |
gptkb:Rituximab
|
gptkbp:bfsParent |
gptkb:Merck_Biosimilars
|
gptkbp:bfsLayer |
6
|